- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01100879
Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy (AOC-MM)
Randomised Controlled Open-label Study to Evaluate Efficacy & Safety of Intravenous Ferric Carboxymaltose Versus no Treatment in Anaemic Subjects With Multiple Myeloma & Iron Restricted Erythropoiesis Receiving Chemotherapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients will be randomised into two groups. One will receive active FCM treatment and the other group will receive local standard of care.
Active treatment group: Subjects will receive a total dose of 1,000 mg iron as FCM on the day of the first scheduled chemotherapy cycle or within 24 hours before or after receiving chemotherapy. In subjects of weight ≤66 kg, the first dose (500 mg) will be administered on the day of the first scheduled chemotherapy cycle and the second dose (500 mg) on the next study visit.
Standard of care group: Subjects will be treated according to the local institutional practice if requiring management of symptomatic anaemia. Intravenous iron should only be used to treat absolute iron deficiency (as defined as ferritin less than the lower limit of normal based on the test reference ranges). Patients with absolute iron deficiency are not eligible for inclusion to the study.
Rescue medication to manage anaemia is permitted in both arms at the discretion of the treating physician and/or per institutional practice.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects (male or female) aged ≥18, suffering from a newly diagnosed or progressed/relapsed MM and scheduled to receive anti-myeloma treatment. Progression is defined according to "Uniform Response Criteria for Multiple Myeloma"
- Subjects with progressed/relapsed MM should have had stable disease (during the last 6 months since prior treatment).
- Life expectancy at least 6 months.
- 8.5 g/dL ≤Hb ≤11 g/dL at time of randomisation.
Iron-restricted erythropoiesis as defined:
- Stainable iron in bone marrow (BM) combined with transferrin saturation (TSAT) ≤20%, or
- where the evaluation of stainable iron in BM is not possible or available:
- ferritin >30 ng/mL (women) or >40 ng/mL (men), and
- TSAT ≤20%
- Females of child-bearing potential must have a negative urine pregnancy test at screening.
- Before any study-specific procedure, the appropriate written informed consent must be obtained.
Exclusion Criteria:
- Any anaemia treatment within 4 weeks prior to randomisation (including red blood cell transfusions, treatment with ESA or any oral/parenteral iron preparations).
- Anthracycline containing chemotherapy regimens.
- Subjects weighing <35 kg.
- Folate deficiency (serum-folate <4.5 nmol/L) and/or Vitamin B12 deficiency (serum-cobalamin <145 pmol/L).
- Ongoing haemolysis defined as serum-haptoglobin <0.2 g/L.
- Known chronic renal failure, glomerular filtration rate <30 mL/min/m2.
- Recent (within last 4 weeks) significant bleeding/surgery, defined as drop in Hb of ≥2 g/dL.
- Clinically relevant active inflammatory disease other than MM (according to the judgement of the Investigator).
- Clinically relevant ongoing infectious disease including known human immunodeficiency virus.
- Serum ferritin >600 ng/mL.
- Ongoing significant neurological or psychiatric disorders including psychotic disorders or dementia.
- Significant cardiovascular disease prior to study inclusion including myocardial infarction within 12 months prior to study inclusion, congestive heart failure New York Heart Association Grade III or IV, or poorly controlled hypertension according to the judgment of the Investigator.
- Elevation of liver enzymes (aspartate aminotransferase, alanine aminotransferase) over 3 times above the normal range or known acute hepatic disorder.
- Subject currently is enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(ies), or subject is receiving other investigational agent(s).
- Subject of child-bearing potential is evidently pregnant (e.g., positive human chorionic gonadotropin test) or is breast feeding.
- Subject is not using adequate contraceptive precautions. Adequate contraceptive precautions are defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intra-uterine devices, sexual abstinence or vasectomised partner. Non-childbearing potential includes being surgically sterilised at least 6 months prior to the study or post-menopausal, defined as amenorrhea for at least 12 months.
- Subject has known sensitivity to any of the products to be administered during dosing.
- Subject will not be available for follow-up assessment.
- Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Ferric carboxymaltose
Subjects will receive a total dose of 1,000 mg iron as FCM on the day of the next scheduled chemotherapy cycle after randomisation or continuous chemotherapy.
In subjects with weight ≤66 kg, the first dose iron will be 500 mg; the second dose (500 mg) will be administered on the visit 3 (week 2).
|
Subjects will receive a single dose of 1,000 mg iron as FCM infusion at baseline. Subjects of bw ≤66 kg will receive a single dose of 500 mg iron as FCM infusion at baseline (Week 0) and at Visit 3 (Week 2). Ferric carboxymaltose will be administered on the same day with chemotherapy treatment or within 24 hours before or after the chemotherapy. For subjects with bw ≤66 kg, if no chemotherapy planned for the visit 4 (Week 2), the second FCM dose should be infused independent of chemotherapy.
Other Names:
|
No Intervention: Local standard of care.
Subjects will be treated according to the local institutional practice.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in haemoglobin (Hb) from baseline to Weeks 4, 6 and 8
Time Frame: week 4, 6 and 8 post baseline
|
Mean change in Hb from baseline to Weeks 4, 6 and 8 (end of treatment) in the absence of any red cell transfusion or erythropoiesis stimulating agents (ESA) treatment.
|
week 4, 6 and 8 post baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of subjects with blood Hb response of at least 1 g/dL
Time Frame: 12 weeks post baseline
|
Percentage of subjects with blood Hb response of at least 1 g/dL in the absence of any red cell transfusion or ESA treatment.
|
12 weeks post baseline
|
Percentage of subjects with a blood Hb correction to at least 12 g/dL
Time Frame: 12 weeks post baseline
|
Percentage of subjects with a blood Hb correction to at least 12 g/dL in the absence of any red cell transfusion or ESA treatment
|
12 weeks post baseline
|
Time to Hb response defined as increase in Hb equal to or more than 1 g/dL
Time Frame: Baseline until end of study (week 8)
|
Median time to Hb response defined as increase in Hb equal to or more than 1 g/dL in the absence of any red cell transfusion or ESA treatment
|
Baseline until end of study (week 8)
|
Subjects receiving red blood cell transfusions or subjects treated with ESA
Time Frame: Baseline until end of study (week 8)
|
Proportion of subjects receiving red blood cell transfusions or subjects treated with ESA during the study period
|
Baseline until end of study (week 8)
|
Adverse events
Time Frame: Baseline until end of study (week 8)
|
Adverse events: type, nature, incidence and outcome
|
Baseline until end of study (week 8)
|
Transfusion/treatment with ESA
Time Frame: Baseline until end of study (week 8)
|
Time to transfusion/treatment with ESA
|
Baseline until end of study (week 8)
|
Change in serum ferritin from baseline to Weeks 2, 4, 6 and 8
Time Frame: week 2, 4, 6, and 8 post baseline
|
Mean change in serum ferritin from baseline to Weeks 2, 4, 6 and 8
|
week 2, 4, 6, and 8 post baseline
|
Change in transferrin saturation (TSAT) from baseline to Weeks 2, 4, 6 and 8
Time Frame: week 2, 4, 6, and 8 post baseline
|
Mean change in TSAT from baseline to Weeks 2, 4, 6 and 8
|
week 2, 4, 6, and 8 post baseline
|
Change in serum iron from baseline to Weeks 2, 4, 6 and 8
Time Frame: week 2, 4, 6, and 8 post baseline
|
Mean change in serum iron from baseline to Weeks 2, 4, 6 and 8
|
week 2, 4, 6, and 8 post baseline
|
Change in endogenous erythropoietin from baseline to Weeks 2, 4, 6 and 8
Time Frame: week 2, 4, 6, and 8 post baseline
|
Mean change in endogenous erythropoietin from baseline to Weeks 2, 4, 6 and 8
|
week 2, 4, 6, and 8 post baseline
|
Change in blood reticulocyte haemoglobin content/red blood cell size factor from baseline to Weeks 2, 4, 6 and 8
Time Frame: week 2, 4, 6, and 8 post baseline
|
Mean change in blood reticulocyte haemoglobin content/red blood cell size factor from baseline to Weeks 2, 4, 6 and 8
|
week 2, 4, 6, and 8 post baseline
|
Change in percentage of hypochromic red cells/percentage of low Hb density from baseline to Weeks 2, 4, 6 and 8
Time Frame: week 2, 4, 6, and 8 post baseline
|
Mean change in percentage of hypochromic red cells/percentage of low Hb density from baseline to Weeks 2, 4, 6 and 8
|
week 2, 4, 6, and 8 post baseline
|
Change in hepcidin from baseline to Weeks 2, 4, 6 and 8
Time Frame: week 2, 4, 6, and 8 post baseline
|
Mean change in hepcidin from baseline to Weeks 2, 4, 6 and 8
|
week 2, 4, 6, and 8 post baseline
|
Change in interleukin-6 from baseline to Weeks 2, 4, 6 and 8
Time Frame: week 2, 4, 6, and 8 post baseline
|
Mean change in interleukin-6 from baseline to Weeks 2, 4, 6 and 8
|
week 2, 4, 6, and 8 post baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Katodritou Eirini, MD, Theagenion Hospital, Thessaloniki, Greece
- Study Director: Timothy R Cushway, Vifor Pharma, CH-8152 Glattbrugg, Switzerland
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Metabolic Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Anemia, Hypochromic
- Iron Metabolism Disorders
- Neoplasms, Plasma Cell
- Multiple Myeloma
- Anemia, Iron-Deficiency
- Anemia
Other Study ID Numbers
- FER-AOC-MM
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Iron-Deficiency Anemia
-
Pennington Biomedical Research CenterRecruitingIron-deficiency | Iron Deficiency Anemia | Iron Deficiency Anemia TreatmentUnited States
-
Children's Hospital Los AngelesNot yet recruitingAnemia | Iron Deficiency Anemia | Anemia, Iron Deficiency | IDA - Iron Deficiency AnemiaUnited States
-
King's CollegeCompletedIron-deficiency | Iron Deficiency Anemia | Iron Deficiency (Without Anemia)United States
-
Arrowhead Regional Medical CenterRecruitingIron Deficiency Anemia of PregnancyUnited States
-
Swiss Federal Institute of TechnologyUnited States Agency for International Development (USAID); Quadram Institute... and other collaboratorsCompletedIron-deficiency | Iron Deficiency Anemia | Iron Deficiency (Without Anemia)Peru
-
Luzerner KantonsspitalRecruitingIron Deficiency Anemia | Iron Deficiency Anemia Treatment | Iron DeficienciesSwitzerland
-
Children's Hospital Los AngelesWithdrawnAnemia | Iron-deficiency Anemia | Healthy ControlsUnited States
-
Baylor College of MedicineNational Heart, Lung, and Blood Institute (NHLBI)CompletedIron-deficiency | Iron Deficiency AnemiaUnited States
-
Iowa State UniversityCompletedIron-deficiency | Iron Deficiency Anemia | Iron Deficiency Anemia Treatment | Iron Deficiency Anaemia Due to Dietary CausesUnited States
-
Société des Produits Nestlé (SPN)CompletedIron-deficiency | Anemia | Iron Deficiency AnemiaPhilippines
Clinical Trials on Ferric carboxymaltose
-
Sichuan Huiyu Pharmaceutical Co., LtdThe First Hospital of Jilin University; Suzhou Guochen Biotek Co., Ltd.; Boji... and other collaboratorsCompletedBioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency AnaemiaIron Deficiency | AnaemiaChina
-
Hasselt UniversityZiekenhuis Oost-LimburgCompleted
-
The Catholic University of KoreaUnknownKnee Osteoarthritis | Total Knee Arthroplasty | Postoperative Anemia
-
The Catholic University of KoreaUnknownKnee Osteoarthritis | Total Knee Arthroplasty | Postoperative Anemia
-
Charite University, Berlin, GermanyUniversity of GöttingenUnknownHeart Failure | Iron-deficiencyGermany
-
St Joseph University, Beirut, LebanonSaint-Joseph University; Vifor PharmaCompletedAnemia, Iron DeficiencyLebanon
-
Istanbul UniversityRecruitingAnemia | Hip Fractures | Complication,PostoperativeTurkey
-
American Regent, Inc.Completed
-
University of ZurichTerminated
-
Jon UnossonNot yet recruitingSurgery | Liver Metastases | Pancreas Cancer | Aortic Aneurysm | Liver CancerSweden